| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 9.99 | 0.09 (+0.91%) | 4.02 - 10.40 | 189.6 thousand (Above Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 9.93 |
|---|---|
| Previous Close | 9.90 |
| Day's Range | 9.89 - 10.05 |
| Market Cap | 359.7M |
| Avg Volume (10 Day) | 139.2K |
| Price/Earnings (Trailing 12 Mo.) | 0.4x |
| Earnings Per Share (Trailing 12 Mo.) | 22.73 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
PR Newswire - Tuesday 06/11/2013 8:00 AM ET
Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
PR Newswire - Tuesday 05/21/2013 4:05 PM ET
| RGLS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.21 | |
| LT Debt/Equity | 0.21 | |
| Earnings Yield | 250.00% | |
| Price/Sales | 38.39 |
| Company | Last | Change |
|---|---|---|
| Immunomedics Inc | 4.43 | +3.02% |
| Repros Therapeutics Inc | 19.20 | +0.05% |
| Osiris Therapeutics Inc | 10.49 | -1.50% |
| Albany Molecular Research Inc | 11.76 | -1.75% |
| Dyax Corp | 3.29 | +1.86% |
Data is delayed by at least 15 min.